Condition
Rasmussen Encephalitis
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Unknown2
Recruiting1
Withdrawn1
Clinical Trials (4)
Showing 4 of 4 trials
NCT05017142Recruiting
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
NCT04003922UnknownPrimary
Study on Patients With Rasmussen Encephalitis Treated With Adalimumab: Efficacy and Tolerance in the Short and Long Term
NCT04344626Not ApplicableWithdrawn
Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery
NCT00545493Phase 2UnknownPrimary
Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis
Showing all 4 trials